Lonza Group AG | 549.40 |
Date/Time | 05/25 / 17:19 |
Chg. / Chg.(%) | - / |
Bid | - |
Ask | - |
Open | 554.40 |
Previous Close | 556.20 |
High | 556.60 |
Low | 546.60 |
Volume [CHF] | 15,170,580.80 |
Volume [Units] | 27,583 |
Price fixings | 2610 |
ISIN | CH0013841017 |
Security | LONN/Z |
Exchange | Cboe Europe CXE |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
Nasdaq Other.. | 565.8270 | ![]() |
10 |
Lang & Schwa.. | 528.400 | ![]() |
|
SIX Swiss Ex.. | 547.80 | ![]() |
|
Cboe Europe .. | 549.40 | 27,583 | |
London Domes.. | 547.80 | 17,759 | |
Cboe Europe .. | 547.80 | 12,369 | |
Turquoise | 549.80 | ![]() |
3,740 |
Mexico | 11,590.38 | ![]() |
295 |
TradeGate | 294.000 | 298 | |
Frankfurt | 293.9000 | 63 | |
Düsseldorf | 291.20 | 0 | |
München | 291.30 | 0 | |
Berlin | 296.90 | 0 | |
Hamburg | 291.30 | 0 | |
gettex | 296.100 | ||
Singapore | 79.97 | 500 | |
EUREX | Options |
News
- Lonza to Acquire Codiak BioSciences Exosomes Manufacturing Facility and Establish a Long-Term Strategic Collaboration
11/02/2021 / 13:00 - GlobeNewswire - Affinia Therapeutics Announces Indications for Lead Gene Therapy Programs to Advance the Treatment of Neurologic and Neuro-oncologic Diseases supported by Multi-Year Manufacturing Agreement with Lonza Group
09/08/2021 / 13:30 - GlobeNewswire - aTyr Pharma and Lonza Announce Manufacturing Agreement for aTyr’s Anti-NRP2 Antibody ATYR2810
04/14/2021 / 14:00 - GlobeNewswire - Altimmune Expands AdCOVID™ Manufacturing Collaboration with Lonza
03/12/2021 / 07:00 - GlobeNewswire - Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications
01/12/2021 / 15:05 - GlobeNewswire